First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.
- In the news
Sonrotoclax becomes the first BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma, showing over 10-fold greater potency than venetoclax.
- Why it matters: This approval addresses the need for new, effective options for patients who have failed BTK inhibitor therapy, filling a critical treatment gap in mantle cell lymphoma.
- What they did: The drug was approved through accelerated processes based on its superior binding affinity and potentially improved safety profile, and is now being tested in phase III trials against venetoclax for chronic lymphocytic leukemia.
- The result: This milestone enables a new mechanistic treatment option for mantle cell lymphoma and may influence future therapies for other B-cell malignancies.